A
couple of points to make, riffing off the tweet below, on the subject of sell-side analysts remaining bullish on Alzheimer’s disease drugs like Biogen’s (BIIB) aducanumab even when the historical failure rate is pretty much 100 percent.
It is amazing to see the probabilities that some analysts put on Aducanumab. Wells put in print that they stay at 60-65% following FDA draft guidelines. I have no idea, but analysts can’t help bullishness in AD $BIIB
— Ty (@HCanalyst) February 16, 2018
Sell-side analysts are smart people who work in a dumb system called Wall Street that basically rewards them for being optimistic, even when the facts — or for biotech analysts, the clinical data — suggest otherwise.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
“If the drug fails, the stock could fall to $250, which is roughly the price at which many analysts set “zero pipeline value” for the company.”
— why would shares in a company with nothing of value in the pipeline be priced at $250/share???